Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ABEONA THERAPEUTICS INC.

(ABEO)
  Report
Delayed Nasdaq  -  04:00 2022-12-09 pm EST
3.120 USD   -0.32%
11/14ABEONA THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS (form 10-Q)
AQ
11/14Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
CI
11/14Abeona Therapeutics : Q3 Earnings Snapshot
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Abeona Therapeutics Announces AAV204, a Novel AAV Capsid, Demonstrated Robust Macular Transduction Following Para-Retinal Administration in Non-Human Primates

05/04/2022 | 07:34am EST

Abeona Therapeutics Inc. announced the presentation of new preclinical data on AAV204 at the Association for Research and Vision in Ophthalmology (ARVO) Annual Meeting, taking place on May 1-4, 2022 in Denver, CO
and virtually on May 11-12, 2022. The data was featured in a poster presentation entitled "AAV204, a Novel AAV Capsid, Demonstrates Superior Macular Transduction Following Para-Retinal Administration in Non-Human Primates." AAV204, a novel adeno-associated virus (AAV) capsid from Abeona's in-licensed AIM(TM) capsid library, has previously been shown to facilitate transduction of both the inner and outer retina after intravitreal administration in mice and non-human primates. The purpose of the current study was to evaluate in non-human primates transduction levels in the macula and optic nerve following administration of AAV204 directly into the vitreous of the eye by para-retinal administration, a recently-developed method, which unlike subretinal administration does not create a retinal detachment.


ę S&P Capital IQ 2022
All news about ABEONA THERAPEUTICS INC.
11/14ABEONA THERAPEUTICS INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION A..
AQ
11/14Abeona Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months..
CI
11/14Abeona Therapeutics : Q3 Earnings Snapshot
AQ
11/14Abeona Therapeutics Reports Third Quarter 2022 Financial Results
GL
11/08Cantor Fitzgerald Adjusts Price Target on Abeona Therapeutics to $40 From $22, Maintain..
MT
11/03Abeona Therapeutics Inc. : Entry into a Material Definitive Agreement, Unregistered Sale o..
AQ
11/03Abeona Therapeutics Says Late-Stage Study of EB-101 Meets Both Co-Primary Efficacy Endp..
MT
11/03Transcript : Abeona Therapeutics Inc. - Special Call
CI
11/03Abeona Therapeutics Inc. : Regulation FD Disclosure, Other Events, Financial Statements an..
AQ
11/03Abeona Therapeutics Announces Positive Topline Results with Both Co-Primary Endpoints M..
AQ
More news
Analyst Recommendations on ABEONA THERAPEUTICS INC.
More recommendations
Financials (USD)
Sales 2022 1,98 M - -
Net income 2022 -53,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,74x
Yield 2022 -
Capitalization 53,6 M 53,6 M -
Capi. / Sales 2022 27,0x
Capi. / Sales 2023 -
Nbr of Employees 90
Free-Float 94,6%
Chart ABEONA THERAPEUTICS INC.
Duration : Period :
Abeona Therapeutics Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ABEONA THERAPEUTICS INC.
Short TermMid-TermLong Term
TrendsBearishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 3,12 $
Average target price 21,33 $
Spread / Average Target 584%
EPS Revisions
Managers and Directors
Vishwas Seshadri President, Chief Executive Officer, COO & Director
Joseph Vazzano Chief Financial & Accounting Officer
Michael Amoroso Chairman
Brian Kevany Chief Technical Officer & Vice President
Todd Wider Independent Director
Sector and Competitors
1st jan.Capi. (M$)
ABEONA THERAPEUTICS INC.-61.54%54
MODERNA, INC.-29.52%70 958
IQVIA HOLDINGS INC.-25.42%39 082
LONZA GROUP AG-39.99%36 246
ALNYLAM PHARMACEUTICALS, INC.36.41%29 282
SEAGEN INC.-18.99%23 253